Bruker showcases high-performance solutions at Analytica 2024 for research and analysis in applied, industrial and biopharma laboratories

FHS
April 9, 2024
11:34 am

Bruker Corporation (Nasdaq: BRKR) is showcasing some of its latest innovations at Analytica 2024:

IGC Pharma heads towards a Phase I study for Alzheimer’s disease – Pharmaceutical Technology

Share this article TGR-63, being developed to target amyloid-beta plaques, has shown preclinical potential in reducing Alzheimer’s-related anxiety. Credits: AtlasStudio/Shutterstock.com With positive preclinical data for

February 2, 2024

Study offers new insights into how ketamine works

A World Health Organization Essential Medicine, ketamine is widely used at varying doses for sedation, pain control, general anesthesia and as a therapy for treatment-resistant

May 21, 2024

How Long Does an Acid Trip Last? | Psychedelic Spotlight

LSD is a potent hallucinogenic substance that has been used for decades to induce psychedelic experiences. Commonly referred to as “acid,” LSD alters perception, thoughts,

July 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.